CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
NASDAQ:CDNA
About AlloSure®
AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory.
http://www.allosure.com/
About AlloMap®
AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.
http://www.allomap.com/
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
NASDAQ:CDNA
About AlloSure®
AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory.
http://www.allosure.com/
About AlloMap®
AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.
http://www.allomap.com/
Location: United States, California, South San Francisco
Employees: 501-1000
Phone: +1 415-287-2300
Founded date: 1998
Investors 2
| Date | Name | Website |
| - | Pivotal Ca... | pivotalcp.... |
| - | Perceptive... | perceptive... |
Mentions in press and media 12
| Date | Title | Description |
| 25.07.2023 | M&A: CareDx Acquires Organ Transplant Company MediGO | What You Should Know: Precision medicine company CareDx acquires MediGO, an organ transplant supply chain and logistics company for an undisclosed sum. The strategic acquisition will expand CareDx’s digital health portfolio to serve the org... |
| 25.07.2023 | CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company | MediGO Platform Aims to Improve Access to Donated Organs and Shorten Transplant Wait Times Acquisition Expands CareDx Digital Health Portfolio and Establishes Footprint in OPO Market CareDx, a leading precision medicine company focused on t... |
| 25.07.2023 | CareDx Buys MediGO | CareDx, a Brisbane, CA-based precision medicine company developing healthcare solutions for transplant patients and caregivers, acquired MediGO, a company which specializes in healthcare supply chain technology and software solutions. The a... |
| 05.03.2023 | CareDx Comments on MolDX Publication of New Billing and Coding Article | Article Addresses Coverage of Molecular Testing for Solid Organ Allograft Rejection Following Contractor Advisory Committee Meetings CareDx, – The Transplant Company focused on the discovery, development, and commercialization of clinically... |
| 23.02.2023 | CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting | CareDx Hosting Pan-Organ Symposium, “Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence” CareDx, a leading precision medicine company focused on the discovery, development, and commercialization of clin... |
| 10.11.2021 | CareDx Acquires Medication Adherence Platform MedActionPlan | What You Should Know: – CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregiv... |
| 23.07.2021 | Is Artificial Intelligence The New Logistics Technology For Organ Transportation? | Air Transport of Organ Donation for Transplantation. Commercial Aviation has great importance in the ... [+] transport of organs for transplants in receiving patients. Studies show that commercial air carriers carry more than 9,000 organs a... |
| 15.12.2020 | CareDx Constantly Revolutionizing Personalized Care for Transplant Recipients | "CareDx is 100% dedicated to transplant patient care...We are at an exciting inflection point as we build comprehensive solutions to enable direct patient engagement and personalized care,” said Peter Maag, Executive Chairman at CareDx... |
| 17.08.2020 | This App Uses AI To Help Transplant Patients Monitor Organ Health | Sign on the back of a vehicle pleading for someone to donate a kidney to a sick man in Mississauga, ... [+] Ontario, Canada. (Photo by Creative Touch Imaging Ltd./NurPhoto via Getty Images)NurPhoto via Getty Images |
| 29.08.2019 | CareDx Buys XynManagement | CareDx, Inc. (Nasdaq: CDNA), a Brisbane, California-based precision medicine company, completed the acquisition of XynManagement, a Boerne, TX-based provider of solutions to simplify transplant quality tracking and waitlist management. The ... |
Show more